Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future

Bibliography

• Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6(1):35-47
   PubMedGoogle Scholar
• National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002–10 – 12 June 2002. Hepatology 2002;36(5 Suppl 1):S3-20
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner AJ, Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359-62
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Nelson DR, Marcellin P. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care? Antivir Ther 2008;13(6):747-60
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461(7262):399-401
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Mullen KD, Jones DB, Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315(25):1575-8
   PubMed Web of Science ®Google Scholar
• Davis GL, Balart LA, Schiff ER, Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321(22):1501-6
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Martin P, Kassianides C, Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321(22):1506-10
   PubMed Web of Science ®Google Scholar
• Marcellin P, Boyer N, Giostra E, Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13(3):393-7
   PubMed Web of Science ®Google Scholar
• Blatt LM, Davis JM, Klein SB, The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996;16(7):489-99
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339(21):1485-92
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS, Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138):1426-32
   PubMed Web of Science ®Google Scholar
• EASL consensus panel. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30(5):956-61
   PubMedGoogle Scholar
• Manns MP, McHutchison JG, Gordon SC, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438-50
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292(23):2839-48
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Bhagani S, Benhamou Y, European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9(2):82-8
   PubMed Web of Science ®Google Scholar
• Muir AJ, Shiffman ML, Zaman A, Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52(3):822-32
   PubMed Web of Science ®Google Scholar
• Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-k) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e10000017
   Google Scholar
• Muir AJ, Lawitz E, Ghalib RH, Pegylated interferon lambda (PEG-IFN-lamda) phase 2 dose-ranging, active-controlled study in combination with ribavirin (RBV) for treatment-naive HCV patients (genotypes 1, 2, 3 or 4): safety, viral response, and impact of IL-28b host genotype through week 12 [abstract 821]. Hepatology 2010;52(Suppl):715A
   PubMedGoogle Scholar
• Muir AJ, Shiffman ML, Zaman A, Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52(3):822-32
   PubMed Web of Science ®Google Scholar
• Subramanian GM, Fiscella M, Lamouse-Smith A, Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007;25(12):1411-19
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Sulkowski M, Lawitz E, Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naive patients with chronic hepatitis C genotype 1. Oral presentation. Available from: www.hgsi.com/albinterferon-alfa-2b.html. [Accessed January 2010]. J Hepatol 2009;50(Suppl 1):S377
   Google Scholar
• Nelson D, Benhamou Y, Chuang WL, Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in interferon alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C. Oral presentation. Available from: www.hgsi.com/albinterferon-alfa-2b.html. [Accessed January 2010]. J Hepatol 2009;50(Suppl 1):S378
   Google Scholar
• Human Genome Sciences. Human Genome Sciences modifies dosing in ACHIEVE trials of Albuferon; Press release 23 January 2008. Available from: http://www.hgsi.com/latest/human-genome-sciences-modifies-dosing-in-achieve-trials-of-albuf-2.html
   Google Scholar
• Human GenomeSciences. Human Genome Sciences announces preliminary feedback from FDA on Zalbin™ BLA for chronic hepatitis C. Press release 14th June 2010. Press release 2010. Available from: http://www.hgsi.com/latest/human-genome-sciences-announces-preliminary-feedback-from-fda-on-zalbin-bla-for-chronic-hepati-2.html
   Google Scholar
• European Medicines Agency. Novartis Europharm Ltd withdraws its marketing authorisation application for Joulferon (albinterferon alfa-2b). 10 A.D.; EMA/249301/2010
   Google Scholar
• Novartis. Novartis discontinues development of two investigational compounds reflecting enhanced focus on portfolio prioritization and productivity. Available from: http://www.novartis.com/newsroom/media-releases/en/2010/1449020.shtml
   Google Scholar
• Schuster D, Laggner C, Langer T. Why drugs fail–a study on side effects in new chemical entities. Curr Pharm Des 2005;11(27):3545-59
   PubMed Web of Science ®Google Scholar
• Hammond TG, Valentin J-P, Smith CG, editors, The process of new drug discovery and development. 2nd edition. Safety pharmacology: past, present, and future; 2006
   Google Scholar
• Jensen DM, Morgan TR, Marcellin P, Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43(5):954-60
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P, Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44(1):97-103
   PubMed Web of Science ®Google Scholar
• Mangia A, Minerva N, Bacca D, Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47(1):43-50
   PubMed Web of Science ®Google Scholar
• Dalgard O, Bjoro K, Hellum KB, Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40(6):1260-5
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352(25):2609-17
   PubMed Web of Science ®Google Scholar
• von Wagner M, Huber M, Berg T, Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129(2):522-7
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR, Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357(2):124-34
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Huang JF, A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56(4):553-9
   PubMed Web of Science ®Google Scholar
• Dalgard O, Bjoro K, Ring-Larsen H, Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47(1):35-42
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Rizzetto M, Ferenci P, Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response. Antivir Ther 2009;14(2):143-54
   PubMed Web of Science ®Google Scholar
• Stattermayer AF, Stauber R, Hofer H, Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2010. [Epub ahead of print]
   Google Scholar
• Thompson AJ, Muir AJ, Sulkowski MS, Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients. Gastroenterology 2010;139(1):120-9
   PubMed Web of Science ®Google Scholar
• Mangia A, Thompson AJ, Santoro R, Interleukin-28B polymorphism determines treatment response of patients with hepatitis c genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010;139(3):821-7
   PubMed Web of Science ®Google Scholar
• Rallon NI, Naggie S, Benito JM, Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24(8):F23-9
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Hirakawa M, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010;52:421-9
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Nelson DR, Andreone P, Phase IIB study of Balapiravir (RG1626; Nucleoside analogue inhibitor of HCV polymerase) plus peginterferon alfa-2a (40KD) and ribavirin for CHC genotype: final results. [abstract]. J Hepatol 2010;52:(1)
   PubMedGoogle Scholar
• Jacobson I. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment naive patients: final results of phase 3 ADVANCE study [abstract 211]. Hepatology 2010;52(Suppl):427A
   Google Scholar
• Poordad F. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis c virus (HCV) genotype (G) 1: SPRINT-2 final results [abstract LB4]. Hepatology 2010;52(Suppl):402A
   Google Scholar
• Gane EJ, Roberts SK, Stedman CA, Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376(9731):1467-75
   PubMedGoogle Scholar
• Hezode C, Forestier N, Dusheiko G, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360(18):1839-50
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. NEJM 2009;360:1827-38
   PubMed Web of Science ®Google Scholar
• Kwo P, Lawitz E, McCone J, HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. J Hepatol 2009;50:(1:54)
   Google Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):S237-44
   PubMed Web of Science ®Google Scholar
• Ferenci P, Brunner H, Nachbaur K, Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34(5):1006-11
   PubMed Web of Science ®Google Scholar
• Jensen DM, Marcellin P, Freilich B, Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009;150(8):528-40
   PubMed Web of Science ®Google Scholar
• Cooper CL, Al Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42(12):1674-8
   PubMed Web of Science ®Google Scholar
• Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol 2010;53(3):455-9
   PubMed Web of Science ®Google Scholar
• Ascione A, De Luca M, Tartaglione MT, Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138(1):116-22
   PubMed Web of Science ®Google Scholar
• Rumi MG, Aghemo A, Prati GM, Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138(1):108-15
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6):580-93
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46(1):37-47
   PubMed Web of Science ®Google Scholar
• Witthoeft T, Hueppe D, John C, Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE Study. J Viral Hepat 2010;17(7):459-68
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Ghalib RH, Hamzeh FM, Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepatitis 2007;14:721-9
   PubMed Web of Science ®Google Scholar
• Awad T, Thorlund K, Hauser G, Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51(4):1176-84
   PubMed Web of Science ®Google Scholar
• Diago M, Crespo J, Olveira A, Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther 2007;26(8):1131-8
   PubMed Web of Science ®Google Scholar
• Roberts SK, Weltman MD, Crawford DH, Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009;50(4):1045-55
   PubMed Web of Science ®Google Scholar
• Marcellin P, Jensen DM, Roberts SK, Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) has a wide safety margin in patients infected with HCV genotype 1. Hepatol Int 2010;4:(1):94-345
   Google Scholar
• Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004;24(Suppl 2):25-31
   PubMedGoogle Scholar
• Schmid M, Kreil A, Jessner W, Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54(7):1014-20
   PubMed Web of Science ®Google Scholar
• Antonini MG, Babudieri S, Maida I, Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008;36(3):250-5
   PubMed Web of Science ®Google Scholar
• Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010;52(4):1225-31
   PubMed Web of Science ®Google Scholar
• Puoti M, Babudieri S, Rezza G, Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004;9(4):627-30
   PubMed Web of Science ®Google Scholar
• Koirala J, Gandotra SD, Rao S, Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007;14(11):782-7
   PubMed Web of Science ®Google Scholar
• Ochi H, Maekawa T, Abe H, Inosine triphosphate pyrophosphatase polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese hepatitis C virus patients. Gastroenterology 2010;139(4):1190-7
   PubMed Web of Science ®Google Scholar
• Fellay J, Thompson AJ, Ge D, ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464(7287):405-8
   PubMed Web of Science ®Google Scholar
• Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009;50(2):402-11
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K, Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123(4):1061-9
   PubMed Web of Science ®Google Scholar
• Bronowicki JP, Ouzan D, Asselah T, Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131(4):1040-8
   PubMed Web of Science ®Google Scholar
• Reddy KR, Shiffman ML, Morgan TR, Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5(1):124-9
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Salvatore J, Hubbard S, Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46(2):371-9
   PubMed Web of Science ®Google Scholar
• Available from: http://web.archive.org/web/20070528103823/http://www.fda.gov/cder/drug/advisory/RHE2007.htm
   Google Scholar
• Sulkowski MS, Shiffman ML, Afdhal NH, Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010;139:1602-11
   PubMed Web of Science ®Google Scholar
• Jensen DM, Freilich B, Andreone P, Easy to assess on-treatement parameters correlate with degree of virological response after 12 weeks of treatment. J Hepatol 2008;48(Suppl 2):S297-8
   Google Scholar
• Lindsay KL, Morishima C, Wright EC, Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008;6(2):234-41
   PubMed Web of Science ®Google Scholar
• F.Hoffmann-La Roche. PEGASYS Summary of Product Characteristics, revised 2010. 2010
   Google Scholar
• Zeuzem S, Yoshida EM, Benhamou Y, Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008;48(2):407-17
   PubMed Web of Science ®Google Scholar
• Demirturk N, Aykin N, Demirdal T, Cevik F. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Eur J Dermatol 2006;16(5):579-80
   PubMed Web of Science ®Google Scholar
• Shafa S, Borum ML, Igiehon E. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy. Eur J Gastroenterol Hepatol 2010;22(1):122-3
   PubMed Web of Science ®Google Scholar
• Taliani G, Biliotti E, Capanni M, Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother 2005;17(2):212-14
   PubMed Web of Science ®Google Scholar
• Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007;19(9):817-20
   PubMed Web of Science ®Google Scholar
• Montaudie H, Passeron T, Cardot-Leccia N, Drug rash with eosinophilia and systemic symptoms due to telaprevir. Dermatology 2010. [Epub ahead of print]
   Google Scholar
• Cheng YC, Chen CC, Ho AS, Prolonged psychosis associated with interferon therapy in a patient with hepatitis C: case study and literature review. Psychosomatics 2009;50(5):538-42
   PubMed Web of Science ®Google Scholar
• Fabregas BC, Moura AS, Marciano RC, Clinical management of a patient with drug dependence who attempted suicide while receiving peginterferon therapy for chronic hepatitis C. Braz J Infect Dis 2009;13(5):387-90
   PubMed Web of Science ®Google Scholar
• Ferenci P, Staufer K. Depression in chronic hepatitis: the virus, the drug, or the ethnic background? Liver Int 2008;28(4):429-31
   PubMed Web of Science ®Google Scholar
• Leutscher PD, Lagging M, Buhl MR, Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010;52(2):430-5
   PubMed Web of Science ®Google Scholar
• Neri S, Bertino G, Petralia A, A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Clin Gastroenterol 2010;44(9):e210-17
   PubMed Web of Science ®Google Scholar
• Schmidt F, Janssen G, Martin G, Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment Pharmacol Ther 2009;30(10):1049-59
   PubMed Web of Science ®Google Scholar
• Raison CL, Woolwine BJ, Demetrashvili MF, Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007;25(10):1163-74
   PubMed Web of Science ®Google Scholar
• Morasco BJ, Rifai MA, Loftis JM, A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007;103(1-3):83-90
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Schottker K, Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008;57(4):531-6
   PubMed Web of Science ®Google Scholar
• Rustgi VK, Esposito S, Hamzeh FM, Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2008;27(5):433-40
   PubMed Web of Science ®Google Scholar
• Tran HA, Attia JR, Jones TL, Batey RG. Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. J Gastroenterol Hepatol 2007;22(4):472-6
   PubMed Web of Science ®Google Scholar
• Tran HA, Reeves GE, Ianna EA, Leembruggen N. Thyroid function outcomes following pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Endocr Pract 2010;1-16
   Google Scholar
• Schering-Plough Ltd. ViraferonPeg (PegIntron) Summary of Product Characteristics, revised 2010. 2010
   Google Scholar
• Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009;15(13):1537-47
   PubMed Web of Science ®Google Scholar
• Dove LM, Rosen RC, Ramcharran D, Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology 2009;137(3):873-84, 884
   PubMed Web of Science ®Google Scholar
• Hofer H, Donnerer J, Sator K, Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy. J Hepatol 2010;52(6):812-16
   PubMed Web of Science ®Google Scholar
• Fernandez-Miranda C, Castellano G, Guijarro C, Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. Am J Gastroenterol 1998;93(10):1901-4
   PubMed Web of Science ®Google Scholar
• Shinohara E, Yamashita S, Kihara S, Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 1997;25(6):1502-6
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Garcia-Escano MD, Valdivielso P, Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. Aliment Pharmacol Ther 2000;14(7):929-35
   PubMed Web of Science ®Google Scholar
• Mandac JC, Chaudhry S, Sherman KE, Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006;43(4):661-72
   PubMed Web of Science ®Google Scholar
• Onishi S, Nagashima T, Kimura H, Systemic lupus erythematosus and Sjogren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus 2010;19(6):753-5
   PubMed Web of Science ®Google Scholar
• Selmi C, Lleo A, Zuin M, Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 2006;7(5):451-6
   PubMed Web of Science ®Google Scholar
• Pellicano R, Smedile A, Peyre S, Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Minerva Gastroenterol Dietol 2005;51(1):55-61
   PubMedGoogle Scholar
• Bell TM, Bansal AS, Shorthouse C, Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol 1999;14(5):419-22
   PubMed Web of Science ®Google Scholar
• Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010;55(3):579-85
   PubMed Web of Science ®Google Scholar
• Tietz A, Liu J, Peng M, Global review of the rate of interstitial pneumonitis among hepatitis virus-C infected patients treated with pegylated interferon +/- ribavirin. Hepatology 2009;50(4 Suppl):676A
   Web of Science ®Google Scholar
• Carrillo-Esper R, Gonzalez-Avila D, Uribe-Rios M, Mendez-Sanchez N. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report. Ann Hepatol 2008;7(1):87-90
   PubMed Web of Science ®Google Scholar
• Lim JW, Shin MC. Pegylated-interferon-associated retinopathy in chronic hepatitis patients. Ophthalmologica 2010;224(4):224-9
   PubMed Web of Science ®Google Scholar
• Formann E, Stauber R, Denk DM, Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004;99(5):873-7
   PubMed Web of Science ®Google Scholar
• Horoldt B, Haydon G, O'Donnell K, Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int 2006;26(6):650-9
   PubMed Web of Science ®Google Scholar
• Bruno S, Shiffman ML, Roberts SK, Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51(2):388-97
   PubMed Web of Science ®Google Scholar
• Tillmann HL, McHutchison JG. Use of thrombopoietic agents for the thrombocytopenia of liver disease. Semin Hematol 2010;47(3):266-73
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Dixit V, Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005;5(6):1452-61
   PubMed Web of Science ®Google Scholar
• Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008;48(5):1690-9
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic P, Boletis J, Besisik F, Low-dose peginterferon alfa-2a (40KD) (PEGASYS) to treat hepatitis C-infected, end-stage renal disease patients undergoing haemodialysis: final study results. J Hepatol 2009;48(Suppl 2):S374
   Google Scholar
• Wang K, Lawal A, Majchrowicz M, Pharmacokinetics of ribavirin in patients with renal impairment or end-stage disease and chronic hepatitis C during treatment with peginterferon alfa-2a (40KD) (PEGASYS®) ribavirin (COPEGUS®). Hepatology 2008;48(S1):1142
   Google Scholar
• Vigani AG, Pavan MH, Tozzo R, Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C. Braz J Infect Dis 2010;14(2):193-6
   PubMed Web of Science ®Google Scholar
• Hakim W, Sheikh S, Inayat I, HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J Clin Gastroenterol 2009;43(5):477-81
   PubMed Web of Science ®Google Scholar
• Goodman ZD, Makhlouf HR, Liu L, Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008;47(3):836-43
   PubMed Web of Science ®Google Scholar
• Guido M, Bortolotti F, Leandro G, Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2003;98(3):660-3
   PubMed Web of Science ®Google Scholar
• Hu J, Doucette K, Hartling L, Treatment of hepatitis C in children: a systematic review. PLoS One 2010;5(7):e11542
   PubMedGoogle Scholar
• Jara P, Hierro L, de la Vega A, Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27(2):142-8
   PubMed Web of Science ®Google Scholar
• Wirth S, Pieper-Boustani H, Lang T, Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41(5):1013-18
   PubMed Web of Science ®Google Scholar